Dorly de Freitas Buchi

Homeopathy Science

About Us

Dorly de Freitas Buchi, a renowned Brazilian researcher, holds a Ph.D. in Biological Sciences (Biophysics) from the Federal University of Rio de Janeiro. Her solid academic background is reflected in the publication of several scientific articles in the field of Cell Biology. Professor, for more than 40 years at the Federal University of Paraná, she combines extensive experience in higher education, both in undergraduate and graduate courses, and effective contributions in the sphere of the university administration. Her orientation activities are remarkable, from scientific initiation to doctorate, having promoted the training of a large number of young scientists.

Despite this exemplary academic trajectory, what makes Dorly a special human being are her unique qualities: loyalty, courage, tenderness, and tenacity. Woman, mother, sister, and friend, she is endowed with profound sensitivity, a conciliatory spirit, and the ability to aggregate people and ideals around a greater good. Her respect for life, in all its forms, has always guided her in search of health promotion and a better life for all. And so, in her continuous overcoming of challenges, guided by an acute scientific curiosity and her non-conformity with the paradigms and limitations of traditional medicine, in an untiring spirit and an unwavering purpose of serving collective interests, firmly carried out research based on highly diluted drugs and complex biological response modifiers. A significant part of the results of her efforts and her holistic view is presented in this book which, as an author, proposes to contribute to life, health, and the construction of happiness for all.

About Homeopathy

Immune System and Homeopathy Studies using macrophages treated with different homeopathic medicines have resulted in a significant increase in the activated/resident macrophage ratio compared to control groups (water, hydroalcoholic solution, and untreated). Different macrophage receptors were altered, both in expression and distribution, in addition to altering the production and release of different cytokines and reactive oxygen and nitrogen species…

Last posts we sent to the blog

Homeopathy Science

  • Like cures like: This principle states that a substance that can cause symptoms in a healthy person can cure those same symptoms in a sick person. For example, if a person gets a rash from contact with poison ivy, then a homeopathic remedy made from poison ivy might be used to treat a rash with similar symptoms.

  • The law of minimums: This principle states that the smaller the dose of a remedy, the greater its effect. Homeopathic remedies are often diluted to very high levels, but practitioners believe that this dilution makes them more effective.

  • The single remedy: This principle states that only one remedy should be given at a time, so that its effects can be clearly observed.

  • The totality of symptoms: This principle states that the remedy should be chosen based on the whole picture of the patient’s symptoms, not just the physical symptoms. This includes the patient’s emotional and mental state, as well as their lifestyle and preferences.

My Book on Amazon

To know more about homeoptahy

Visit our blog

The existence and unexpected pathways in my life.

In this book, I tell the story of my life and my relationship with science, and especially how this journey resulted in 20 years of basic research in homeopathy.


Gallusstrasse 1a 8730 Uznach


The immune system has numerous ways to protect us from viruses. One of them is the production of specific antibodies against some epitopes of the virus by B-Lymphocytes (Plasmocytes). Some memory B lymphocytes that produce these antibodies can be selected and reserved to defend us in a new attack from the same virus. Another type of defense involves cytotoxic T lymphocytes that destroy cells that are infected, preventing the virus from replicating.

This immunity can be permanent, long-term, that is, it can last for years and it is with this objective that vaccine producers work, trying to obtain this long-term defense response. Unfortunately, this is not always possible, as is the case with HIV. To give a safe response to the population, researchers need to monitor antibody levels for longer to find out. It is also important to monitor whether these antibodies will remain at a low concentration – as is common with viral infections – or whether they will decrease rapidly.

When the researchers followed up on patients with COVID-19 throughout that year, they found that the number of antibodies peaked in the days following the onset of symptoms, and then began to decrease. In several of these patients, the antibodies were virtually undetectable in about three months. To determine how significant this decline can be, researchers still need to know how much antibody is needed to successfully ward off SARS-CoV-2.

If immunity to the virus lasts less than a year, for example, like other circulating human coronaviruses, there may be annual increases in COVID-19 infections until 2025 and beyond. Researchers know little so far about how long immunity against SARS-CoV-2 lasts.

But, as was said at the beginning, antibody production is not the only form of immune protection; memory B and T cells also defend against future encounters with the virus, and little is known so far about their role in SARS-CoV-2 infection. For a clear answer on immunity, researchers will need to follow many people for a long time.

Across the world, epidemiologists are building short- and long-term projections to prepare for and potentially mitigate the spread and impact of SARS-CoV-2. Although their predictions and timelines vary, researches agree on two things: COVID-19 is here to stay and the future depends on many unknowns, including whether people develop lasting immunity to the virus, whether seasonality affects its spread, among other factors.

The results also suggest that there may be some lasting cross-immunity between common flu coronaviruses and SARS-CoV-2. If this really happens, it could explain, in part, the great differences in the severity of COVID-19 symptoms among infected individuals. The researchers try to understand the human immune response to SARS-CoV-2 using animals and cell cultures, along with the latest molecular techniques.

They cataloged antibody and immune cell responses with unusual speed, determined which are probably the most effective, and developed vaccines and therapies that, in animal studies and small human studies, elicit at least short-term immune responses.

But there is no quick and simple experiment that can safely determine whether immunity will be effective or long-lasting. It is too early to know. Memory B cells remain in the bone marrow until the virus returns. But data on the role of memory B cells in driving away COVID-19 is incomplete – cells are more difficult to locate and count than antibodies.

A recent study, which has not yet been peer-reviewed, found memory B cells capable of producing neutralizing antibodies that recognize SARS-CoV-2 in people who recovered from mild COVID-19. Permanent immunity for COVID-19 would be ideal, as it would reduce the risk of people with minimal symptoms spreading the infection so easily.

However, these scenarios are only guessing, because this pandemic has so far not followed the pattern of pandemic flu; we have no precedent to compare with the current pandemic. Even a vaccine providing incomplete protection would help to reduce the severity of the disease and prevent hospitalization.

Still, it will take months to produce and distribute a successful vaccine. In the meantime, we need to keep the innate defenses activated. For this we have the M8 immunomodulator complex. As observed over many years of research, M8 quickly activates macrophages and other defense cells, even without direct contact, but also through the production of small molecules such as nitrous oxide and cytokines.

For those interested in a more in-depth discussion consult – Nature, Vol 585, 3 September 2020; 23 November 2020; Nature vol586, 653 (2020).

Dorly de Freitas Buchi

Homeopathy Science